Compare BTU & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | QURE |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | Netherlands |
| Employees | 6600 | 248 |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2001 | 2013 |
| Metric | BTU | QURE |
|---|---|---|
| Price | $22.11 | $24.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $30.92 | ★ $60.30 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,861,500,000.00 | $13,107,000.00 |
| Revenue This Year | $9.76 | $54.76 |
| Revenue Next Year | $10.47 | $356.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.06 | $8.73 |
| 52 Week High | $41.14 | $51.72 |
| Indicator | BTU | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 41.87 |
| Support Level | $21.98 | $24.00 |
| Resistance Level | $24.53 | $25.61 |
| Average True Range (ATR) | 1.05 | 1.33 |
| MACD | -0.07 | 1.14 |
| Stochastic Oscillator | 6.21 | 78.27 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.